What the FDA labels say about taking them together
Aliskiren and losartan
Losartan's FDA label of January 20, 2026 names aliskiren in its contraindications section; aliskiren's label does not name losartan itself but warns about its class (ARBs (angiotensin II receptor blockers)). The losartan label: “Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, syncope, hyperkalemia, and …”
Check it at the source: the aliskiren FDA label on DailyMed (effective March 7, 2024, LXO US Inc.); the losartan FDA label on DailyMed (effective January 20, 2026, Organon LLC).
What does the aliskiren label say about losartan?
Aliskiren's label does not name losartan itself; it warns about its class (ARBs (angiotensin II receptor blockers)):
Aliskiren label, warnings and precautionsRenal Impairment/Hyperkalemia/Hypotension when Tekturna is Given in Combination with ARBs or ACEIs Tekturna is contraindicated in patients with diabetes who are receiving ARBs or ACEIs because of the increased risk of renal impairment, hyperkalemia, and hypotension.
Aliskiren label, contraindicationsCONTRAINDICATIONS Do not use Tekturna with ARBs or ACEIs in patients with diabetes [see Warnings and Precautions ( 5.2 ) and Clinical Studies ( 14.3 )].
Source: FDA drug label (Tekturna), NDA021985 (Lxo Ireland), as published by LXO US Inc., effective March 7, 2024 (SPL set 3dd61fa5-1620-4ebf-bbdb-ede29b92fce2), via openFDA; the full label on DailyMed
What does the losartan label say about aliskiren?
Losartan label, contraindicationsFor coadministration with aliskiren in patients with diabetes.
Losartan label, drug interactionsBlockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy.
Source: FDA drug label (Arbli, NDA218772), Scienture LLC, effective October 3, 2025 (SPL set afd2d1ba-e7af-4e4e-8b7e-a9f72612fc97), via openFDA
Source: FDA drug label (COZAAR), Organon LLC, effective January 20, 2026 (SPL set 9949448f-c3b9-44ee-94ed-c1aca8c90f39), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Aliskiren | Losartan | |
|---|---|---|
| Labeled for | High blood pressure | High blood pressure, Chronic kidney disease, Stroke prevention |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $3.94 per tablet 150 mg tablet | $0.0327 per tablet 50 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once